Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615927 · ClinicalTrials.gov registry record · Phase 2
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00615927 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 64 participants.
The verdict
NCT00615927, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
Primary objective: * To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: * To evaluate progression-free survival (PFS), overall survival and objective response rate among patients with progressive/recurrent grade II LGG treated with imatinib mesylate plus hydroxyurea * To assess safety and tolerability of imatinib mesylate + hydroxyurea in this population
Interventions
- DRUG Imatinib Mesylate & Hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615927
The ClinicalTrials.gov registry entry for NCT00615927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib Mesylate & Hydroxyurea is the first listed.
NCT00615927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615927 about?
NCT00615927 is a clinical study titled "Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)". Primary objective: * To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: * To evaluate progression-free survival (PFS), overall survival and obje...
What is the current status of trial NCT00615927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2006-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00615927?
The interventions under investigation include: Imatinib Mesylate & Hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00615927?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.